X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Alvotech will develop AVT06 (Aflibercept) biosimilar to Eylea. Advanz Pharma will be responsible for registration and commercializing in Europe, except for Germany and France.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: AVT06
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Advanz Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 19, 2024
Details:
The partnership aims to cover AVT03, a clinical-stage biosimilar candidate referencing the Prolia®/Xgeva® (denosumab) medicines for osteoporosis and cancer-related bone loss respectively.
Lead Product(s): Denosumab
Therapeutic Area: Musculoskeletal Product Name: AVT03
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: STADA Arzneimittel
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 11, 2024
Details:
The collaboration aims for commercialization of AVT03 (denosumab), a monoclonal antibody and a biosimilar to Prolia & Xgeva. It is a RANK ligand inhibitor, being evaluated in bone loss in adult men.
Lead Product(s): Denosumab
Therapeutic Area: Musculoskeletal Product Name: AVT03
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Dr. Reddy\\\'s Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 21, 2024
Details:
Alvotech will manufacture its high-concentration interchangeable biosimilar, AVT02, a monoclonal antibody and that has been approved as a biosimilar to Humira (adalimumab) for Quallent.
Lead Product(s): Adalimumab
Therapeutic Area: Immunology Product Name: AVT02
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Quallent Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 30, 2024
Details:
AVT05 (golimumab) is a tumor necrosis factor (TN) blocker indicated for the treatment of moderately to severely active rheumatoid arthritis in adults, active psoriatic aithritis & active ankylosing spondylitis in adults.
Lead Product(s): Golimumab
Therapeutic Area: Immunology Product Name: AVT05
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 24, 2024
Details:
The agreement aims to further enhance access to Simlandi (adalimumab-ryvk) in the U.S. market, the newly U.S. Food and Drug Administration (FDA) approved high-concentration interchangeable biosimilar to Humira.
Lead Product(s): Adalimumab
Therapeutic Area: Immunology Product Name: Simlandi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 19, 2024
Details:
Selarsdi (ustekinumab-biosimilar) is a human IgG1κ monoclonal antibody (mAb) which inhibits IL-12 & Il-23. It is approved by EMA for the treatment of crohn’s disease, psoriasis and psoriatic arthritis.
Lead Product(s): Ustekinumab
Therapeutic Area: Dermatology Product Name: Selarsdi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Teva Pharmaceutical Industries
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2024
Details:
Simlandi (adalimumab) is the first interchangeable, high-concentration, citrate-free biosimilar to Humira approved for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis and Crohn’s disease.
Lead Product(s): Adalimumab
Therapeutic Area: Immunology Product Name: Simlandi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Teva Pharmaceutical Industries
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2024
Details:
AVT03 (denosumab) is a human monoclonal antibody and a biosimilar candidate to Prolia & Xgeva. It is a RANK ligand inhibitor, which is being evaluated in phase 1 trials for bone loss in adult men.
Lead Product(s): Denosumab
Therapeutic Area: Musculoskeletal Product Name: AVT03
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2024
Details:
Uzpruvo (ustekinumab-biosimilar) is a human IgG1κ monoclonal antibody (mAb) which inhibits IL-12 & Il-23. It is approved by EMA for the treatment of crohn’s disease, psoriasis and psoriatic arthritis.
Lead Product(s): Ustekinumab
Therapeutic Area: Gastroenterology Product Name: Uzpruvo
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: STADA Arzneimittel
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
